concomitant uveitis (since uveitis may respond to MTX therapy), and if the current TNFi biologic is infliximab or adalimumab (for immunogenicity prevention). Under circumstances in which combination therapy with a TNFi biologic and MTX is used and active PsA persists, switching to a different TNFi with MTX is recommended over monotherapy with a different TNFi. Continuing MTX treatment during TNFi transition was seen as beneficial because TNFi biologics may have more sustained efficacy when used